Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/3/2011

2 million, from $15.1 million reported for the same period in 2009. This increase was primarily due to the company's commercial launch preparations in the fourth quarter of 2010, including the hiring of hospital sales specialists and medical science liaisons.  Partially offsetting this increase was a reduction in Cadence's pre-commercial manufacturing expenses incurred in the fourth quarter of 2010 as compared to the comparable period in 2009.

Operating expenses for the year ended December 31, 2010, increased $10.4 million to $54.9 million, from $44.5 million reported for 2009. This increase was primarily due to a significant increase in Cadence's sales and marketing expenses as a result of preparations for the commercial launch of OFIRMEV, including developing a commercial infrastructure and the addition of headcount to support the launch. Partially offsetting these increases was a decrease in Cadence's research and development expenses, primarily due to the discontinuation of Cadence's omiganan pentahydrochloride development program in March 2009 and the completion of its clinical development program for OFIRMEV in May 2009.

As of December 31, 2010, Cadence held cash, cash equivalents and short-term investments of $134.1 million. Included in the balance at December 31, 2010, were the proceeds from Cadence's fourth quarter public offering, in which 12.5 million shares of common stock were sold, raising net proceeds of $93.6 million.

Commenting on the 2010 financial results and recent events, Ted Schroeder, President and CEO of Cadence, stated, "I'm extremely proud of how quickly our team mobilized to launch OFIRMEV and I'm excited by the speed at which hospitals are adding OFIRMEV to their formularies. We believe that this strong early recognition of the role that OFIRMEV may play in addressing the longstanding unmet need to provide improved pain management to hospitalized patients bodes well for broad utilization in U.S. hospitals. We al
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
2. Cadence Pharmaceuticals to Present at Two Investment Conferences in February 2011
3. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
4. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results on November 5, 2010
7. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
8. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
9. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
10. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... Dental Economics, the author explained how many dental practices across the country are ... Assisted Manufacturing) technology. According to Beverly Hills cosmetic dentist Dr. Sam Saleh of ...
(Date:9/1/2015)... ... , ... According to a study published August 25th in the ... a three year study about weight loss and diabetes were far more likely to ... surgery at the onset of the trial. In fact, the participants in the trial ...
(Date:9/1/2015)... ... 2015 , ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted ... on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on the eve ... fashion and professional hair, makeup and nail design. , The evening of beauty ...
(Date:9/1/2015)... ... ... Georgia State University and its partners have introduced a ... assaults on their campuses. , The free, evidence-based survey was developed by the ... student affairs professionals responding to calls by the Obama Administration to strengthen efforts ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... collaboration, announces Splashtop Business for Remote Support , a solution optimized for ... Unhappy with the escalating renewal prices and inadequate customer services of existing ...
Breaking Medicine News(10 mins):Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... , , , ... Clinically Superior When Its Own FDA-Approved Label Said Otherwise; First-Ever ... , PHILADELPHIA, Sept. 2 Pfizer Inc. ignored a ... clinically superior to the significantly less expensive, generic vancomycin when its ...
... , , , ... DIET ), a leading provider of online weight loss services, ... creative boutique that specializes in DRTV commercials, to lead creative turnaround beginning ... service. , , "We are really impressed by ...
... 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... China, announced,today that it has signed an agreement with ... collaborate on marketing,efforts and possible vaccine supply efforts to ... The agreement follows meetings between ...
... of the body,s immune system in the development of diseases ... skin cancer), type 1 diabetes, autoimmune liver disease, and in ... paved the way for a pioneering research programme which aims ... find ways to extract specific cells which play a role ...
... , , , , ... STRM ) announced today that it will release second quarter ... on Wednesday, September 9, 2009 after the market closes. The Company will ... Wednesday, September 9 at 4:30 p.m. ET. , , ...
... Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... of BioMarin, will present a company update at the Thomas Weisel Partners ... ET. , , Interested parties may access ... of the BioMarin website, www.BMRN.com . A replay ...
Cached Medicine News:Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 2Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 3Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 4Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 5Health News:eDiets.com Selects Karlin+Pimsler to Lead Creative Turnaround 2Health News:Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea 2Health News:Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea 3Health News:Biomedical Research Centre developing enhanced cells as therapies 2Health News:Biomedical Research Centre developing enhanced cells as therapies 3Health News:Streamline Health to Announce Second Quarter Fiscal Year 2009 Financial Results on Wednesday, September 9, 2009 2Health News:Streamline Health to Announce Second Quarter Fiscal Year 2009 Financial Results on Wednesday, September 9, 2009 3Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: